5 results about "Lung abscess" patented technology

The invention relates to a therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess. [Problem] The present invention relates to a safer and more effective therapeutic agent for respiratory tract infections. [Solution] A therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess, said agent containing, as an active ingredient, 7-[(3S, 4S)-3-{(cyclopropylamino) methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

The invention relates to a preparation method of a traditional Chinese medicine composition for treating pulmonary abscess, which can effectively solve the problem of medication for treating pulmonary abscess. The oral liquid is prepared from the following raw material medicines: fresh rehmannia, fresh houttuynia cordata, fresh scutellaria baicalensis, fresh ginseng and gecko, and is prepared by cleaning, slicing, water adding, wall breaking, filtering, centrifuging, ultrafiltration, concentrating, freeze-drying, crushing, sieving, uniform mixing, vacuum packaging and sterilizing. The traditional Chinese medicine composition is prepared through a specific method according to the main and secondary relation of monarch, minister, assistant and guide, plays a synergistic effect, has the effects of clearing away lung-heat and detoxifying, dispersing blood stasis and eliminating carbuncle, strengthening the body resistance to eliminate pathogenic factors, and removing stasis and dredging collaterals, can be effectively used for treating pulmonary abscess, is simple in preparation method, convenient to operate, safe and environment-friendly, can keep active ingredients in the traditional Chinese medicines to the greatest extent, and has a remarkable curative effect on treating pulmonary abscess. The traditional Chinese medicine composition is free of toxic and side effects, has very good practical clinical application value and development and application prospects, and has huge economic and social benefits.

The utility model belongs to the field of negative pressure drainage apparatuses, particularly relates to a medical disposable negative pressure drainage apparatus for lung abscess interventional puncture, and aims to solve the problems that an existing negative pressure drainage apparatus for lung abscess interventional puncture is high in material consumption, high in manufacturing cost and inconvenient to take and place due to the fact that the existing negative pressure drainage apparatus cannot be supported in shape when in use, and comprises a top cover, a containing bag and a bottom plate. An air suction vertical pipe is arranged at the top of the top cover, an injection connecting pipe is arranged at the top of the top cover, a liquid outlet valve is arranged on one side of the bottom of the containing bag, supporting rods are arranged on the two sides of the containing bag, the two supporting rods are supported between the top cover and the bottom plate, and scale marks are arranged on the sides, away from each other, of the two supporting rods. The supporting rod can be folded and stored, the overall structure is compact and convenient to carry and store, the blocking quality can be guaranteed through the design of the arc-shaped angle of the floating block, and therefore the overall structural design is more reasonable, all parts are connected more tightly, and operation is easier.

The present invention is a therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess. [Problem] The present invention relates to a safer and more effective therapeutic agent for respiratory tract infections. [Solution] A therapeutic agent for inhalation pneumonia, pulmonary suppuration or pulmonary abscess, said agent containing, as an active ingredient, 7-[(3S, 4S)-3-{(cyclopropylamino) methyl}-4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.